Skip to main content
PMC home page
Heart logoLink to Heart
. 2001 Dec;86(6):656–660. doi: 10.1136/heart.86.6.656

Prognostic significance of cardiac 123I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study

H Ogita 1, T Shimonagata 1, M Fukunami 1, K Kumagai 1, T Yamada 1, Y Asano 1, A Hirata 1, M Asai 1, H Kusuoka 1, M Hori 1, N Hoki 1
PMCID: PMC1730035  PMID: 11711461

Abstract

OBJECTIVE—To determine whether cardiac iodine-123 metaiodobenzylguanidine (123I MIBG) imaging is useful in predicting the prognosis of patients with chronic heart failure.
DESIGN—Cardiac 123I MIBG imaging was done on entry to the study. The cardiac MIBG washout rate was calculated from anterior chest view images obtained 20 and 200 minutes after injection of the isotope. Study patients were divided into two groups with washout rates above and below 27% (the mean value + 2 SD obtained in 20 normal subjects), and were then followed up.
SETTING—Tertiary referral centre.
PATIENTS—79 patients with chronic heart failure in whom the left ventricular ejection fraction was less than 40%.
RESULTS—There were 37 patients in group 1 (washout rate of ⩾ 27%) and 42 in group 2 (< 27%). During a follow up period of between 1 and 52 months, eight patients died suddenly and five died of worsening heart failure in group 1, while none died in group 2; 13 patients in group 1 and four in group 2 were admitted to hospital for progressive heart failure. Kaplan-Meier analysis showed that group 1 had a significantly higher mortality and morbidity (p = 0.001 and p < 0.001, respectively) than group 2.
CONCLUSIONS—Cardiac 123I MIBG washout rate seems to be a good predictor of prognosis in patients with chronic heart failure.


Keywords: chronic heart failure; sudden death; cardiac adrenergic nerve activity

Full Text

The Full Text of this article is available as a PDF (141.2 KB).

Figure 1  .

Figure 1  

Open in a new tab

Comparison of morbidity and mortality curves between groups 1 and 2. Group 1 contained 37 patients whose cardiac MIBG washout rate was 27% or more. Group 2 contained 42 patients whose cardiac MIBG washout rate was less than 27%. Both morbidity (A) and mortality (B) were significantly higher in group 1 than in group 2 (p = 0.001 and p < 0.001, respectively).

Figure 2  .

Figure 2  

Open in a new tab

Comparison of morbidity and mortality curves in the ischaemic heart disease subgroup. Group 1 of this subgroup contained 20 patients and group 2 contained 25 patients. Both morbidity (A) and mortality (B) were significantly higher in group 1 than in group 2 (p = 0.047 and p < 0.001, respectively).

Figure 3  .

Figure 3  

Open in a new tab

Comparison of mortality and morbidity curves in the non-ischaemic heart disease subgroup. Both group 1 and group 2 of this subgroup contained 17 patients. Both morbidity (A) and mortality (B) were significantly higher in group 1 than in group 2 (p = 0.014 and p < 0.001, respectively).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abramson F. B., Furst C. I., McMartin C., Wade R. The isolation, identification and synthesis of two metabolites of guanethidine formed in pig and rabbit liver homogenates. Biochem J. 1969 Jun;113(1):143–156. doi: 10.1042/bj1130143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cohen-Solal A., Esanu Y., Logeart D., Pessione F., Dubois C., Dreyfus G., Gourgon R., Merlet P. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol. 1999 Mar;33(3):759–766. doi: 10.1016/s0735-1097(98)00608-1. [DOI] [PubMed] [Google Scholar]
  3. Cohn J. N., Levine T. B., Olivari M. T., Garberg V., Lura D., Francis G. S., Simon A. B., Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984 Sep 27;311(13):819–823. doi: 10.1056/NEJM198409273111303. [DOI] [PubMed] [Google Scholar]
  4. Eichhorn E. J., McGhie A. L., Bedotto J. B., Corbett J. R., Malloy C. R., Hatfield B. A., Deitchman D., Willard J. E., Grayburn P. A. Effects of bucindolol on neurohormonal activation in congestive heart failure. Am J Cardiol. 1991 Jan 1;67(1):67–73. doi: 10.1016/0002-9149(91)90102-q. [DOI] [PubMed] [Google Scholar]
  5. Florea V. G., Henein M. Y., Cicoira M., Anker S. D., Doehner W., Ponikowski P., Francis D. P., Gibson D. G., Coats A. J. Echocardiographic determinants of mortality in patients >67 years of age with chronic heart failure. Am J Cardiol. 2000 Jul 15;86(2):158–161. doi: 10.1016/s0002-9149(00)00853-5. [DOI] [PubMed] [Google Scholar]
  6. Foti A., Kimura S., DeQuattro V., Lee D. Liquid-chromatographic measurement of catecholamines and metabolites in plasma and urine. Clin Chem. 1987 Dec;33(12):2209–2213. [PubMed] [Google Scholar]
  7. Gasnier B., Roisin M. P., Scherman D., Coornaert S., Desplanches G., Henry J. P. Uptake of meta-iodobenzylguanidine by bovine chromaffin granule membranes. Mol Pharmacol. 1986 Mar;29(3):275–280. [PubMed] [Google Scholar]
  8. Goris M. L., McKillop J. H., Briandet P. A. A fully automated determination of the left ventricular region of interest in nuclear angiocardiography. Cardiovasc Intervent Radiol. 1981;4(2):117–123. doi: 10.1007/BF02552390. [DOI] [PubMed] [Google Scholar]
  9. Hasking G. J., Esler M. D., Jennings G. L., Burton D., Johns J. A., Korner P. I. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986 Apr;73(4):615–621. doi: 10.1161/01.cir.73.4.615. [DOI] [PubMed] [Google Scholar]
  10. Imamura Y., Ando H., Mitsuoka W., Egashira S., Masaki H., Ashihara T., Fukuyama T. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. J Am Coll Cardiol. 1995 Dec;26(7):1594–1599. doi: 10.1016/0735-1097(95)00374-6. [DOI] [PubMed] [Google Scholar]
  11. Jaques S., Jr, Tobes M. C., Sisson J. C., Baker J. A., Wieland D. M. Comparison of the sodium dependency of uptake of meta-lodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol Pharmacol. 1984 Nov;26(3):539–546. [PubMed] [Google Scholar]
  12. Kawai C., Yui Y., Hoshino T., Sasayama S., Matsumori A. Myocardial catecholamines in hypertrophic and dilated (congestive) cardiomyopathy: a biopsy study. J Am Coll Cardiol. 1983 Nov;2(5):834–840. doi: 10.1016/s0735-1097(83)80229-0. [DOI] [PubMed] [Google Scholar]
  13. Merlet P., Benvenuti C., Moyse D., Pouillart F., Dubois-Randé J. L., Duval A. M., Loisance D., Castaigne A., Syrota A. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med. 1999 Jun;40(6):917–923. [PubMed] [Google Scholar]
  14. Merlet P., Valette H., Dubois-Randé J. L., Moyse D., Duboc D., Dove P., Bourguignon M. H., Benvenuti C., Duval A. M., Agostini D. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992 Apr;33(4):471–477. [PubMed] [Google Scholar]
  15. Momose M., Kobayashi H., Iguchi N., Matsuda N., Sakomura Y., Kasanuki H., Kusakabe K., Okawa T. Comparison of parameters of 123I-MIBG scintigraphy for predicting prognosis in patients with dilated cardiomyopathy. Nucl Med Commun. 1999 Jun;20(6):529–535. doi: 10.1097/00006231-199906000-00007. [DOI] [PubMed] [Google Scholar]
  16. Sahn D. J., DeMaria A., Kisslo J., Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978 Dec;58(6):1072–1083. doi: 10.1161/01.cir.58.6.1072. [DOI] [PubMed] [Google Scholar]
  17. Schofer J., Spielmann R., Schuchert A., Weber K., Schlüter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1988 Nov;12(5):1252–1258. doi: 10.1016/0735-1097(88)92608-3. [DOI] [PubMed] [Google Scholar]
  18. Schofer J., Tews A., Langes K., Bleifeld W., Reimitz P. E., Mathey D. G. Relationship between myocardial norepinephrine content and left ventricular function--an endomyocardial biopsy study. Eur Heart J. 1987 Jul;8(7):748–753. doi: 10.1093/eurheartj/8.7.748. [DOI] [PubMed] [Google Scholar]
  19. Senni M., Tribouilloy C. M., Rodeheffer R. J., Jacobsen S. J., Evans J. M., Bailey K. R., Redfield M. M. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998 Nov 24;98(21):2282–2289. doi: 10.1161/01.cir.98.21.2282. [DOI] [PubMed] [Google Scholar]
  20. Somsen G. A., van Vlies B., de Milliano P. A., Borm J. J., van Royen E. A., Endert E., Lie K. I. Increased myocardial [123I]-metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure. Heart. 1996 Sep;76(3):218–222. doi: 10.1136/hrt.76.3.218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sugrue D. D., Rodeheffer R. J., Codd M. B., Ballard D. J., Fuster V., Gersh B. J. The clinical course of idiopathic dilated cardiomyopathy. A population-based study. Ann Intern Med. 1992 Jul 15;117(2):117–123. doi: 10.7326/0003-4819-117-2-117. [DOI] [PubMed] [Google Scholar]
  22. Tobes M. C., Jaques S., Jr, Wieland D. M., Sisson J. C. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med. 1985 Aug;26(8):897–907. [PubMed] [Google Scholar]
  23. Wakasugi S., Wada A., Hasegawa Y., Nakano S., Shibata N. Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine. J Nucl Med. 1992 Feb;33(2):208–214. [PubMed] [Google Scholar]
  24. Wieland D. M., Brown L. E., Rogers W. L., Worthington K. C., Wu J. L., Clinthorne N. H., Otto C. A., Swanson D. P., Beierwaltes W. H. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med. 1981 Jan;22(1):22–31. [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES